| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2bc3cd38be4159a9d62aaff66478491 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-553
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-556
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8146 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57 |
| filingDate |
1993-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fd76c153a6fa1c1005a4b147307d8b30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38a39cb8005b249ef9bb5ae9b8a1a425
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d59ea58d4d1734d461dba2222fbc9ec7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b855107eabcd5d0f093a645f6d08490 |
| publicationDate |
1996-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0670737-A4 |
| titleOfInvention |
IN VIVO PEPTIDE THERAPY. |
| abstract |
Method for treatment of a patient having a normal level of activity of a naturally occurring protein, or having a condition characterized by the presence of an elevated or reduced level of that natural protein. The method includes administering to the patient nucleic acid which encodes an agonist or inhibitory polypeptide of the biological activity of the natural protein, or of a naturally occurring effector which affects the biological activity of that natural protein. The agonist or inhibitor is a polypeptide (i.e. an amino acid chain including at least 2 amino acids, and generally up to about 500 amino acids) expressed from the nucleic acid when that nucleic acid is present in the patient. This agonist and inhibitory polypeptide act in vivo to increase or reduce respectively the specific biological activity of the natural protein or the naturally occurring effector in the patient. |
| priorityDate |
1992-03-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |